SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Re <u>Bahrt Kenneth</u>	porting Person [*]	2. Issuer Name and Ticker or Trading Symbol Oncobiologics, Inc. [ONS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O ONCOBIOLOGICS, INC. 7 CLARKE DRIVE		3. Date of Earliest Transaction (Month/Day/Year) 05/13/2016	X Officer (give title Other (specify below) below) Chief Medical Officer
(Street) CRANBURY NJ (City) (State	08521	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130. 4)
Common Stock	05/13/2016	Р		2,000	A	(1)	2,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Warrants (right to buy)	\$6.6	05/13/2016		Р		1,000		(2)	02/18/2017	Common Stock	1,000	\$0.00 ⁽¹⁾	1,000	D	
Series B Warrants (right to buy)	\$8.5	05/13/2016		р		1,000		(2)	05/18/2018	Common Stock	1,000	\$0.00 ⁽¹⁾	1,000	D	

Explanation of Responses:

1. The reported securities are included within 2,000 Units purchased by the reporting person for \$6.00 per Unit. Each Unit consists of one share of common stock, one half of a Series A warrant to purchase one share of common stock and one half of a Series B Warrant to purchase one share of common stock

2. The Series A Warrants and Series B Warrants will be exercisable 30 days after 5/12/16 or on such date the underwriters separate the units, whichever date is earlier.

Remarks:

<u>/s/ Lawrence Kenyon,</u> Attorney-in-Fact

05/17/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.